SUSMED,Inc.

4263

JP3319150003

IT Services & Consulting

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
537 ^JPY	-0.56%		0.00%	-59.78%

2023	SUSMED,Inc.(TSE:4263) added to S&P Global BMI Index	CI
2022	Walgreens Boots Alliance, Inc. Joins Sustainable Medicines Partnership	CI

SUSMED,Inc. has completed an IPO in the amount of ¥3.65613 billion.

December 24, 2021 at 12:00 am EST

SUSMED,Inc. has completed an IPO in the amount of ¥3.65613 billion.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,593,000
PriceRange: ¥1410
Discount Per Security: ¥112.8

Transaction Features: Sponsor Backed Offering

Latest news about SUSMED,Inc.

SUSMED,Inc.(TSE:4263) added to S&P Global BMI Index	23-09-18	CI
Walgreens Boots Alliance, Inc. Joins Sustainable Medicines Partnership	22-10-04	CI
Aculys Pharma and SUSMED Enter into A Contract to Conduct the Clinical Trial Utilizing Blockchain Technology	22-07-12	CI
Certain Common Stock of SUSMED,Inc. are subject to a Lock-Up Agreement Ending on 21-JUN-2022.	22-06-20	CI
Certain Common Stock of SUSMED,Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2022.	22-03-22	CI
CollaboCreate Co., Ltd. announced that it has received funding from SUSMED,Inc.	22-03-09	CI
Shionogi Signs up to $41 Million Commercialization Contract for Insomnia App	21-12-28	MT
Shionogi & Co., Ltd. Announces Commercialization Agreement with SUSMED Co., Ltd. for Digital Therapeutic App for Insomnia	21-12-27	CI
SUSMED,Inc. has completed an IPO in the amount of ¥3.65613 billion.	21-12-24	CI
SUSMED,Inc. has filed an IPO.	21-11-19	CI
SUSMED Co., Ltd. announced that it has received funding from Suzuken Co., Ltd.	20-10-29	CI
SUSMED Co., Ltd. announced that it expects to receive funding from Suzuken Co., Ltd.	20-10-26	CI
SUSMED Co., Ltd. announced that it has received ¥200 million in funding from Sumitomo Corporation	20-08-24	CI
SUSMED Co., Ltd. announced that it expects to receive funding from Suzuken Co., Ltd.	20-05-10	CI
SUSMED Co., Ltd. announced that it has received ¥720 million in funding from Tokyo Century Corporation, M3, Inc., SBI Investment Co., Ltd., Beyond Next Ventures Inc., Sony Innovation Fund, The Dai-Ichi Life Insurance Company, Limited	18-06-03	CI

Chart SUSMED,Inc.

Duration

Period

More charts

Company Profile

Susmed Inc is a Japan-based company mainly engaged in the digital therapeutics (DTx) development business. The Company operates through two business segments. The DTx Product segment is engaged in the development of application software products for treating diseases such as insomnia, breast cancer, chronic kidney diseases and others. The DTx Platform segment is engaged in the provision of general-purpose clinical trial systems and machine learning automatic analysis systems, as well as the provision of DTx development support services using systems.

Sector

IT Services & Consulting

Calendar

2024-05-09 - Q3 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for SUSMED,Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other IT Services & Consulting

	1st Jan change	Capi.
SUSMED,INC.	-59.78%	58.25M
ACCENTURE PLC	-10.65%	197B
IBM	+12.56%	169B
TATA CONSULTANCY SERVICES LTD.	+1.58%	166B
AUTOMATIC DATA PROCESSING, INC.	+5.85%	101B
RELX PLC	+5.69%	76.87B
CROWDSTRIKE HOLDINGS, INC.	+16.57%	71.98B
INFOSYS LIMITED	-6.73%	71.09B
SNOWFLAKE INC.	-22.12%	51.76B
HCL TECHNOLOGIES LIMITED	+2.81%	48.08B

Other IT Services & Consulting

SUSMED,Inc.

Equities

4263

JP3319150003

IT Services & Consulting

SUSMED,Inc. has completed an IPO in the amount of ¥3.65613 billion.

Latest news about SUSMED,Inc.

Chart SUSMED,Inc.

Company Profile

Income Statement Evolution

Ratings for SUSMED,Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other IT Services & Consulting